Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report

Meersseman W, Van Wijngaerden E (2007) Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med 33:1679–1681 Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA, Glupczynski Y, Installe EJ (2001) Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 27:59–67 Maris C, Martin B, Creteur J, Remmelink M, Piagnerelli M, Salmon I, Vincent JL, Demetter P (2007) Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch 450:329–333 Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D (2007) Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10:1–10 Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Resp Crit Care Med 177:27–34 Tasci S, Glasmacher A, Lentini S, Tschubel K, Ewig S, Molitor E, Sauerbruch T, Luderitz B, Rabe C (2006) Pseudomembranous and obstructive Aspergillus tracheobronchitis: optimal diagnostic strategy and outcome. Mycoses 49:37–42 Chang SM, Kuo HT, Lin FJ, Tzen CY, Sheu CY (2005) Pseudomembranous tracheobronchitis caused by Aspergillus in immunocompromized patients. Scand J Infect Dis 37:937–942 Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415 Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 46:327–360 Maertens J, Raad I, Petrikkos G, Borgaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571 Peleg AY, Woods ML (2004) Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrobl Chem 54:803–808 Andes D, Safdar N, Marchillo K, Conklin R (2006) Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations liposomal AMB and AMB lipid complex in murine candidiasis models. Antimicrob Ag Chemother 50:674–684 Klepser ME, Wolfe EJ, Pfaller MA (1998) Antifungal pharmacidynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother 41:397–401 Sionov E, Mendlovic S, Segal E (2006) Efficacy of amphotericin B or amphotericin-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 53:131–139 Trof RJ, Beishuizen A, bets-Ossenkopp YJ, Girbes ARJ, Groeneveld ABJ (2007) Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 33:1694–1703